(ii) The early cognitive decline based on predominant α-synuclein-driven pathology offers the opportunity to address PD-associated dementia with disease-modifying agents in a clearly defined prodromal phase preceding dementia and based on clear biological stratification. The gene discussed is SNCA; the disease is Parkinson disease.